With the recent approval of new hepatitis C treatments, payers are increasingly concerned with controlling costs in this category through policies that may affect treatment decisions.
The United Kingdom’s National Institute for Health and Care Excellence (NICE) is recommending Solvaldi as a cost-effective option to treat some people who have chronic hepatitis C.
Between developing its own pipeline of therapies for patients with hepatitis C and acquiring another company known for its work in this field, it looks like Merck is taking steps to be a larger player in HCV market.
An emerging epidemic of acute hepatitis C threatens the country’s younger population, which experienced a significant hike in the number of cases during a recent 6-year period, according to a compound study that looked at trends of the disease among youth.
Nonmedical prescription opiate use is linked to the dramatic increase in heroin use from 2007 to 2012, according to a study from New York University's Center for Drug Use and HIV Research.
US health officials estimate that over three million Americans currently have chronic hepatitis C -- most of whom don't know it because the infection usually causes no symptoms. But with recent treatment advances, hepatitis C could become rare by 2036, researchers report in the August 5 issue of the Annals of Internal Medicine.